Market closed
Adaptive Biotechnologies/$ADPT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Ticker
$ADPT
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
709
Website
ADPT Metrics
BasicAdvanced
$1.2B
-
-$1.08
1.49
-
Price and volume
Market cap
$1.2B
Beta
1.49
52-week high
$8.95
52-week low
$2.28
Average daily volume
1.6M
Financial strength
Current ratio
2.894
Quick ratio
2.693
Long term debt to equity
104.483
Total debt to equity
109.967
Interest coverage (TTM)
-13.41%
Management effectiveness
Return on assets (TTM)
-16.17%
Return on equity (TTM)
-62.49%
Valuation
Price to revenue (TTM)
6.798
Price to book
6.03
Price to tangible book (TTM)
15.22
Growth
Revenue change (TTM)
5.10%
Earnings per share change (TTM)
-30.50%
3-year revenue growth (CAGR)
5.06%
3-year earnings per share growth (CAGR)
-9.79%
What the Analysts think about ADPT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Adaptive Biotechnologies stock.
ADPT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ADPT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ADPT News
AllArticlesVideos
Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewsWire·2 weeks ago
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Adaptive Biotechnologies stock?
Adaptive Biotechnologies (ADPT) has a market cap of $1.2B as of February 24, 2025.
What is the P/E ratio for Adaptive Biotechnologies stock?
The price to earnings (P/E) ratio for Adaptive Biotechnologies (ADPT) stock is 0 as of February 24, 2025.
Does Adaptive Biotechnologies stock pay dividends?
No, Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders as of February 24, 2025.
When is the next Adaptive Biotechnologies dividend payment date?
Adaptive Biotechnologies (ADPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Adaptive Biotechnologies?
Adaptive Biotechnologies (ADPT) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.